Product Description: Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori[1][2][3].
Formula: C17H16FN3O2S
Citations: Br J Clin Pharmacol. 2019 Jul;85(7):1454-1463./Toxicol Appl Pharmacol. 2024 Apr 28:486:116945./Drug Dev Res. 2022 Dec 9./Drug Metab Dispos. 2016 Oct;44(10):1543-9. /Eur J Med Chem. 2024 Dec 5.
References: [1]Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456./[2]Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238./[3]Sugimoto M, et al. Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Front Pharmacol. 2019 Jan 15;9:1560.
CAS Number: 881681-00-1
Molecular Weight: 345.399
Compound Purity: 99.89
Research Area: Endocrinology; Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Bacterial;Proton Pump
Deutsch
English
